Effect of continuous silymarin administration on oral talinolol pharmacokinetics in healthy volunteers

References

• Anderle P, Niederer E, Rubas W, Hilgendorf C, Langguth HS, Allenspach HW, Merkle HP, Langguth P. (1998). P-glycoprotein (P-gp) mediated efflux in Caco-2 cell monolayers: the influence of culturing conditions and drug exposure on P-gp expression levels. J Pharm Sci 87:757–62.
   PubMed Web of Science ®Google Scholar
• Assmann I. (1995). The actions of talinolol, a β 1 -selective beta blocker, in cardiac arrhythmia and acute myocardial infarction. Curr Med Res Opin 13:325–42.
   PubMed Web of Science ®Google Scholar
• Beate T, Oertel R, Richter K. (1995). Disposition and bioavailability of the β1-adrenoceptor antagonist talinolol in man. Biopharm Drug Dispos 16:403–14.
   PubMed Web of Science ®Google Scholar
• Beckmann-Knopp S, Rietbrock S, Weyhenmeyer R, Bocker RH, Beckurts KT, Lang W, Hunz M, Fuhr U. (2000). Inhibitory effects of silibinin on cytochrome P-450 enzymes in human liver microsomes. Pharmacol Toxicol 86:250–6.
   PubMedGoogle Scholar
• Campeanu A. (2001). The Cardiac Insufficiency Talinolol Study (CITAS) study design. Eur J Heart Failure 3:377–80.
   PubMed Web of Science ®Google Scholar
• Cascorbi I. (2006). Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol Therapeut 112:457–73.
   PubMed Web of Science ®Google Scholar
• Cascorbi I, Gerloff T, Johne A, Meisel C, Hoffmeyer S, Schwab M, Schaeffeler E, Eichelbaum M, Brinkmann U, Roots I. (2001). Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects. Clin Pharmacol Ther 69:169–74.
   PubMed Web of Science ®Google Scholar
• Filly J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, Decosterd LA, Furrer H, Opravil M, Pantaleo G, Retelska D, Ruiz L, Schinkel AH, Vernazza P, Eap CB, Telenti A. (2002). Response to antiretroviral treatment in HIV-l-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 359:30–6.
   PubMed Web of Science ®Google Scholar
• Ferenci P, Dragosics B, Dittrich H, Frank H, Benda L, Lochs H, Meryn S, Base W, Schneider B. (1989). Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver. J Hepatol 9:105–13.
   PubMed Web of Science ®Google Scholar
• Fuhr U, Beckmann-Knopp S, Jetter A, Lück H, Mengs U. (2007). The effect of silymarin on oral nifedipine pharmacokinetics. Planta Med 73:1429.
   PubMed Web of Science ®Google Scholar
• Gazak R, Walterova D, Kren V. (2007). Silybin and silymarin — new and emerging applications in medicine. Curr Med Chem 14:315–38.
   PubMed Web of Science ®Google Scholar
• Giessmann T, May K, Modess C, Wegner D, Hecker U, Zschiesche M, Dazert P, Grube M, Schroeder E, Warzok R, Cascorbi I, Kroemer HK, Siegmund W. (2004). Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans. Clin Pharmacol Ther 76:192–200.
   PubMed Web of Science ®Google Scholar
• Gurley BJ, Barone GW, Williams DK, Carrier J, Breen P, Yates CR, Song P, Hubbard MA, Tong Y, Cheboyina S. (2006). Effect of milk thistle (Silybum marianum) and black cohosh(cimicifuga racemosa) supplementation on digoxin pharmacokinetics in humans. Drug Metab Disposit 34:69–74.
   PubMed Web of Science ®Google Scholar
• Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Carrier J, Khan IA, Edwards DJ, Shah A. (2004). In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. Clin Pharmacol Ther 76:428–40.
   PubMed Web of Science ®Google Scholar
• He J, Terhaag B, Yang LY, Zhang BK, Su FL, Zhu YG, Song J, Tang J, Liu XL, Peng WX. (2007). Determination of talinolol in human plasma by high performance liquid chromatography- electrospray ionization mass spectrometry: Application to pharmacokinetic study. J Chromatogr B 853:275–80.
   PubMed Web of Science ®Google Scholar
• Hitzl M, Drescher S, Van der Kuip H, Scha¨ffeler E, Fischer J, Schwab M, Eichelbaum M, Fromm MF. (2001). The C3435T mutation in the human MDR1 gene is associated with altered efflux of the P-glycoprotein substrate rhodamine 123 from CD56+ natural killer cells. Pharmacogenetics 11:293–8.
   PubMedGoogle Scholar
• Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U. (2000). Functional polymorphism of the human multidrug- resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97:3473–8.
   PubMed Web of Science ®Google Scholar
• Kvasnicka KF, Bíba B, ševčík R, Voldřich M, Krátká J. (2003). Analysis of the active components of silymarin. J Chromatogr A 990:239–45.
   PubMed Web of Science ®Google Scholar
• Leber HW, Knauff S. (1976). Influence of silymarin on drug metabolizing enzymes in rat and man. Arzneimittelforschung 26:1603–5.
   PubMed Web of Science ®Google Scholar
• Maurer HH, Tenberken O, Kratzsch C, Armin A, Weber, Peters FT. (2004). Screening for library-assisted identification and fully validated quantification of 22 beta-blockers in blood plasma by liquid chromatography-mass spectrometry with atmospheric pressure chemical ionization. J Chromatogr A 1058:169–81.
   PubMed Web of Science ®Google Scholar
• Patel J, Buddha B, Dey S, Pal D, Mitra AK. (2004). In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity. Am J Therapeut 11:262.
   PubMedGoogle Scholar
• Salmi HA, Sarna S. (1982). Effect of silymarin on chemical, functional, and morphological alterations of the liver. A double-blind controlled study. Scand J Gastroenterol 17:517–21.
   PubMed Web of Science ®Google Scholar
• Schulz HU, Schuerer M, Krumbiegel G, Wachter W, Weyhenmeyer R, Seidel G. (1995). Investigation of dissolution and bioequivalence of silymarin products. Arzneimittelforschung 45:61–5.
   PubMed Web of Science ®Google Scholar
• Schwarz UI, Gramatté T, Krappweis J, Oertel R, Kirch W. (2000). P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans. Int J Clin Pharmacol Ther 38:161–7.
   PubMed Web of Science ®Google Scholar
• Schwarz UI, Hanso H, Oertel R, Miehlke S, Kuhlisch E, Glaeser H, Hitzl M, Dresser GK, Kim RB, Kirch W. (2007). Induction of intestinal P-glycoprotein by St John’s wort reduces the oral bioavailability of talinolol. Clin Pharmacol Ther. 81:669–78.
   PubMed Web of Science ®Google Scholar
• Siegmund W, Ludwig K, Engel G, Zschiesche M, Franke G, Hoffmann A, Terhaag B, Weitschies W. (2003). Variability of intestinal expression of P-glycoprotein in healthy volunteers as described by absorption of talinolol from four bioequivalent tablets. J Pharm Sci 92:604–10.
   PubMed Web of Science ®Google Scholar
• Simanek V, Kren V, Ulrichova J, Vicar J, Cvak L. (2000). Silymarin: what is in the name? An appeal for a change of editorial policy. Hepatology 32:442–4.
   PubMed Web of Science ®Google Scholar
• Spahn-Langguth H, Langguth P. (2001). Grapefruit juice enhances intestinal absorption of the P-glycoprotein substrate talinolol. Eur J Pharmaceut Sci 12:361–7.
   PubMed Web of Science ®Google Scholar
• Sridar C, Goosen TC, Kent UM, Williams JA, Hollenberg PF. (2004). Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases. Drug Metab Dispos 32:587–94.
   PubMed Web of Science ®Google Scholar
• Tanabe M, Ieiri I, Nagata N, Inoue K, Ito S, Kanamori Y, Takahashi M, Kurata Y, Kigawa J, Higuchi S, Terakawa N, Otsubo K. (2001). Expression of P-glycoprotein in human placenta:Relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 297:1137–43.
   PubMed Web of Science ®Google Scholar
• Venkataramanan R, Ramachandran V, Komoroski BJ, Zhang S, Schiff PL, Strom SC. (2000). Milk thistle, a herbal supplement, decreases the activity of CYP3A4 and uridine diphosphoglucuronosyl transferase in human hepatocyte cultures. Drug Metab Dispos 8:1270–3.
   Google Scholar
• Weitschies W, Bernsdorf A, Giessmann T, Zschiesche M, Modess C, Hartmann V, Mrazek C, Wegner D, Nagel S, Siegmund Werner. (2005). The talinolol double-peak phenomenon is likely caused by presystemic processing after uptake from gut lumen. Pharmacol Res 22:728–35.
   Web of Science ®Google Scholar
• Zhang S, Morris ME. (2003a). Effects of the flavonoids biochanin a, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. J Pharmacol Exp Ther 304:1258–67.
   PubMed Web of Science ®Google Scholar
• Zhang S, Morris ME. (2003b). Effect of the flavonoids biochanin A and silymarin on the P-glycoprotein-mediated transport of digoxin and vinblastine in human intestinal Caco-2 cells. Pharmacol Res 20:1184–91.
   Web of Science ®Google Scholar
• Zuber R, Modrianský M, Dvorák Z, Rohovský P, Ulrichová J, šimánek V, Anzenbacher P. (2002). Effect of silybin and its congeners on human liver microsomal cytochrome P450 activities. Phytother Res 16:632–8.
   PubMed Web of Science ®Google Scholar